Academic Journal
Q1Cancer Drug Resistance
About Cancer Drug Resistance
Cancer Drug Resistance is a scholarly journal published by OAE Publishing Inc.. SCImago 2025 lists it in Q1, with an SJR of 1.775 and H-index of 36.
Coverage: 2018-2025. Research categories: Cancer Research (Q1); Pharmacology (medical) (Q1).
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Cancer Cells and Metastasis; Cancer Genomics and Diagnostics; MicroRNA in disease regulation; Epigenetics and DNA Methylation; Cancer, Hypoxia, and Metabolism.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Adaptive drug resistance in melanoma is characterised by lipidome remodelling while maintaining cell membrane biophysical properties
Aurélie H. Benfield, Reuben S. E. Young, Grégoire J. B. Philippe, Nicholas D. Condon et al.
2026-09-16 · DOI: 10.20517/cdr.2026.54PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy
Hongrui Liu, Liang Ma, Yixuan Wang, Yuheng Wang et al.
2026-09-07 · DOI: 10.20517/cdr.2026.80Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?
Wolfram C. M. Dempke, Klaus Fenchel, Loretta Sullivan, Martin Reck et al.
2026-09-03 · DOI: 10.20517/cdr.2026.79ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer
Yuxi Yang, Binghui Liang, Weijie Hong, Sau Har Lee et al.
2026-08-31 · DOI: 10.20517/cdr.2026.66Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them
Marco Pagano Mariano, Enrica Sgarilli, Dirk Mijnlieff, Bonifiya Visuvasam et al.
2026-08-31 · DOI: 10.20517/cdr.2026.52Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerability
Tung-Wei Hsu, Chih-Ming Su, Yen-Hao Su, Po-Hsiang Liao et al.
2026-08-24 · DOI: 10.20517/cdr.2026.58Mitochondrial LINC01133 regulates pyroptosis and calcium homeostasis in cisplatin-resistant lung adenocarcinoma
Feiyi Xu, Can Zhang, Sihan Wu, Yang Li et al.
2026-08-11 · DOI: 10.20517/cdr.2026.39TET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cells
Eleicy Nathaly Mendoza, Serena Castelli, Angela De Cristofaro, Enrico Desideri et al.
2026-08-03 · DOI: 10.20517/cdr.2026.42Mechanistic roles and clinical applications of tertiary lymphoid structures in colorectal cancer drug resistance
Zhiliang Li, Wenqing Jia, Zichao Guo, Fang Zheng et al.
2026-07-28 · DOI: 10.20517/cdr.2026.35An epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancer
Xiaonan Shen, Hao Zhong, Wenqing Jia, Zichao Guo et al.
2026-07-27 · DOI: 10.20517/cdr.2026.37Lack of resolution of inflammation marks malignant pleural mesothelioma progression
Veronica Gatti, Matti van Welzen, Alessandro Napoli, Marc Dubourdeau et al.
2026-07-23 · DOI: 10.20517/cdr.2026.33LINC01607 promotes hepatocellular carcinoma progression and ferroptosis-associated therapy resistance with functional involvement of the p62–Keap1–Nrf2 pathway
Yuxin Zhang, Weiqi Xu, Fangling Cheng, Jinghan Zhu et al.
2026-07-17 · DOI: 10.20517/cdr.2026.02Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy
Gesine Kretzschmar, Youssif Budagaga, Lisa Groß, Jan-Heiner Küpper et al.
2026-06-08 · DOI: 10.20517/cdr.2026.10A systematic review and network meta analysis of first-line immunotherapy for advanced urothelial carcinoma
Yang Liu, Yuxuan Song, Jilin Wu, Jincong Li et al.
2026-06-05 · DOI: 10.20517/cdr.2026.22Fenretinide in cancer therapy and chemoprevention: past, present and future
Paola Verachi, Federica Francescangeli, Rosanna Dattilo, Alessandro Vici et al.
2026-06-05 · DOI: 10.20517/cdr.2025.210Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinoma
Yujia Zhang, Yicheng Zhu, Zichang Liu, Haonan Li et al.
2026-05-19 · DOI: 10.20517/cdr.2026.27Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer
Lijun Li, Yanbin Zhao, Xinhong Shi, Xiaotian Guo et al.
2026-05-15 · DOI: 10.20517/cdr.2026.12TRAP1 ablation improves mitochondrial cristae and oxidative phosphorylation in pancreatic cancer stem cells
Giulia Ambrosini, Elisa Dalla Pozza, Ilaria Cristanini, Sara Vinco et al.
2026-05-15 · DOI: 10.20517/cdr.2025.229Tumor heterogeneity as a driver of drug resistance and its implications for personalized therapy
Erhan Da, Ronglan Zhu, Bin Xi, Liyang Zhang et al.
2026-05-12 · DOI: 10.20517/cdr.2025.216Novel N-chloroacetyl-2-pyrazoline analogs with 2-naphthyl and ferrocenyl groups: targeting histamine receptor H1 to overcome colorectal cancer drug resistance
Dileepkumar Veeragoni, Hindole Ghosh, Affan Ansari, Sangita Bhattacharyya et al.
2026-04-30 · DOI: 10.20517/cdr.2025.203Reviews
Community Reviews
Version History
September 25, 2026 at 7:13 am
September 25, 2026